ImExHS (ASX:IME) said its product, Aquila+, an AI-driven radiology platform, is being implemented for new contracts as its major software development is now complete, according to a Monday Australian bourse filing.
The company said it will formally launch the product in Latin America in April, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.